Behavior of deteriogenic fungi in aviation fuels (fossil and biofuel) during simulated storage

Biofuels are expected to play a major role in reducing carbon emissions in the aviation sector globally. Farnesane ("2,6,10-trimethyldodecane") is a biofuel derived from the synthesized iso-paraffin route wich can be blended with jet fuel; however, the microbial behavior in farnesane/jet fuel blends remains unknown. The chemical and biological stability of blends should be investigated to ensure they meet the quality requirements for aviation fuels. This work aimed at evaluating the behavior of two fungi Hormoconis resinae (F089) and Exophiala phaeomuriformis (UFRGS Q4.2) in jet fuel, farnesane, and in 10% farnesane blend during simulated storage. Microcosms (150-mL flasks) were assembled with and without fungi containing Bushnell & Haas mineral medium for 28 days at a temperature of 20±2°C. The fungal growth (biomass), pH, surface tension, and changes in the fuel's hydrocarbon chains were evaluated. This study revealed thatthe treatment containing H. resinae showed a biomass of 19 mg, 12 mg, and 2 mg for jet fuel, blend, and farnesane respectively. The pH was reduced from 7.2 to 4.3 observed in jet fuel treatment The degradation results showed that compounds with carbon chains between C9 and C11, in jet fuel, and blend treatments were preferably degraded. The highest biomass (70.9 mg) produced by E. phaeomuriformis was in 10% farnesane blend, after 21 days. However, no significant decrease was observed on pH and surface tension measurements across the treatments as well as on the hydrocarbons when compared to the controls. This study revealed that farnesane neither inhibited nor promoted greater growth on both microorganisms.

Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetyl-β-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes

Urinary biomarkers can predict the progression of chronic kidney disease (CKD). In this study, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and N-acetyl-β-D-glucosaminidase (NAG) were correlated with the stages of CKD, and the association of these biomarkers with CKD progression and adverse outcomes was determined. A total of 250 patients, including 111 on hemodialysis, were studied. Urinary KIM-1, NGAL, and NAG were measured at baseline. Patients not on dialysis at baseline who progressed to a worse CKD stage were compared with those who did not progress. The association of each biomarker and selected covariates with progression to more advanced stages of CKD, end-stage kidney disease, or death was evaluated by Poisson regression. NGAL was moderately correlated (r^s=0.467, P<0.001) with the five stages of CKD; KIM-1 and NAG were also correlated, but weakly. Sixty-four patients (46%) progressed to a more advanced stage of CKD. Compared to non-progressors, those patients exhibited a trend to higher levels of KIM-1 (P=0.064) and NGAL (P=0.065). In patients not on dialysis at baseline, NGAL was independently associated with progression of CKD, ESKD, or death (RR=1.022 for 300 ng/mL intervals; CI=1.007-1.037, P=0.004). In patients on dialysis, for each 300-ng/mL increase in urinary NGAL, there was a 1.3% increase in the risk of death (P=0.039). In conclusion, urinary NGAL was associated with adverse renal outcomes and increased risk of death in this cohort. If baseline urinary KIM-1 and NGAL predict progression to worse stages of CKD is something yet to be explored.